[{"address1": "500 Technology Square", "address2": "Suite 700", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 586 3100", "website": "https://foghorntx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 112, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adrian H. B. Gottschalk", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 885701, "exercisedValue": 0, "unexercisedValue": 2001808}, {"maxAge": 1, "name": "Dr. Anna  Rivkin Ph.D.", "age": 50, "title": "Chief Business Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 348672, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerald R. Crabtree M.d.", "title": "Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven F. Bellon Ph.D.", "age": 59, "title": "Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 572600, "exercisedValue": 0, "unexercisedValue": 10145}, {"maxAge": 1, "name": "Ms. Karin  Hellsvik", "title": "Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. LaCascia J.D.", "age": 59, "title": "Chief Legal Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 565500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Saurabh  Sewak Ph.D.", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carlos  Costa", "age": 51, "title": "Chief People Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alfonso Quintas Cardama M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 300161, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Garcia-Webb Ph.D.", "title": "VP & Chief of Staff Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 6, "overallRisk": 6, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.0, "open": 4.04, "dayLow": 3.86, "dayHigh": 4.43, "regularMarketPreviousClose": 4.0, "regularMarketOpen": 4.04, "regularMarketDayLow": 3.86, "regularMarketDayHigh": 4.43, "payoutRatio": 0.0, "beta": 3.051, "forwardPE": -2.7594936, "volume": 160016, "regularMarketVolume": 160016, "averageVolume": 170755, "averageVolume10days": 323590, "averageDailyVolume10Day": 323590, "bid": 4.32, "ask": 4.4, "bidSize": 1, "askSize": 1, "marketCap": 246563616, "fiftyTwoWeekLow": 2.945, "fiftyTwoWeekHigh": 9.7, "allTimeHigh": 28.265, "allTimeLow": 2.7, "priceToSalesTrailing12Months": 10.056433, "fiftyDayAverage": 4.6506, "twoHundredDayAverage": 4.644025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 88814624, "profitMargins": -2.94159, "floatShares": 26827366, "sharesOutstanding": 56551289, "sharesShort": 838817, "sharesShortPriorMonth": 895987, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0148, "heldPercentInsiders": 0.18677, "heldPercentInstitutions": 0.72677004, "shortRatio": 5.27, "shortPercentOfFloat": 0.0224, "impliedSharesOutstanding": 56529969, "bookValue": -1.586, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -72122000, "trailingEps": -1.14, "forwardEps": -1.58, "enterpriseToRevenue": 3.622, "enterpriseToEbitda": -1.067, "52WeekChange": -0.56896555, "SandP52WeekChange": 0.1198014, "quoteType": "EQUITY", "currentPrice": 4.36, "targetHighPrice": 14.0, "targetLowPrice": 9.0, "targetMeanPrice": 11.66667, "targetMedianPrice": 11.5, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 180278000, "totalCashPerShare": 3.188, "ebitda": -83225000, "totalDebt": 22529000, "quickRatio": 2.119, "currentRatio": 2.164, "totalRevenue": 24518000, "revenuePerShare": 0.39, "returnOnAssets": -0.21067, "grossProfits": -59410000, "freeCashflow": -10392500, "operatingCashflow": -88347000, "revenueGrowth": 0.044, "grossMargins": -2.42312, "ebitdaMargins": 0.0, "operatingMargins": -2.2692301, "financialCurrency": "USD", "symbol": "FHTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "regularMarketChangePercent": 9.0, "regularMarketPrice": 4.36, "shortName": "Foghorn Therapeutics Inc.", "longName": "Foghorn Therapeutics Inc.", "epsTrailingTwelveMonths": -1.14, "epsForward": -1.58, "epsCurrentYear": -1.166, "priceEpsCurrentYear": -3.7392797, "fiftyDayAverageChange": -0.29059982, "fiftyDayAverageChangePercent": -0.062486522, "twoHundredDayAverageChange": -0.28402472, "twoHundredDayAverageChangePercent": -0.06115917, "priceToBook": -2.7490544, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-23", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1603459800000, "postMarketChangePercent": -2.0642235, "postMarketPrice": 4.27, "postMarketChange": -0.09000015, "regularMarketChange": 0.36, "regularMarketDayRange": "3.86 - 4.43", "postMarketTime": 1762561596, "regularMarketTime": 1762549201, "exchange": "NGM", "messageBoardId": "finmb_538076136", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 170755, "fiftyTwoWeekLowChange": 1.4150002, "fiftyTwoWeekLowChangePercent": 0.48047546, "fiftyTwoWeekRange": "2.945 - 9.7", "fiftyTwoWeekHighChange": -5.3399997, "fiftyTwoWeekHighChangePercent": -0.5505154, "fiftyTwoWeekChangePercent": -56.896557, "earningsTimestamp": 1762349400, "earningsTimestampStart": 1762349400, "earningsTimestampEnd": 1762349400, "isEarningsDateEstimate": false, "displayName": "Foghorn Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-08"}]